What is the potential risk associated with the use of silver silvadiazine for burn treatment?

• A. It can cause leukopenia
• B. It is very painful
• C. It may lead to fluid overload
• D. It penetrates eschar poorly

Answer: (A)

Silver sulfadiazine is a topical antimicrobial agent frequently used in the treatment of burn wounds to prevent and treat infections. One of the recognized potential risks associated with its use is the development of leukopenia, which refers to a decrease in the white blood cell count. This condition can occur due to the drug's sulfadiazine component, which can cause bone marrow suppression, leading to a reduced production of leukocytes. Monitoring the white blood cell count is essential in patients receiving this treatment, especially in those who may already be immunocompromised.

The other options present considerations that, while relevant to patient care, do not specifically correlate with the significant risk profile associated with silver sulfadiazine. While it can be painful and may lead to fluid overload in certain patients, these are not the principal concerns linked to its use in treating burns. The concern about poor penetration through eschar is also valid; however, this primarily pertains to its efficacy rather than a direct adverse effect like leukopenia, which can have immediate health ramifications. Therefore, the association of silver sulfadiazine with leukopenia is a well-documented and critical risk that warrants careful observation during its therapeutic use.